Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Opthea (ASX/NASDAQ:OPT) has announced its participation in the 43rd Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Opthea (ASX/NASDAQ:OPT) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Frederic Guerard will present on January 15, 2025, at 5:15 PM PT, providing a business update that includes masked patient demographics and baseline characteristics from the sozinibercept Phase 3 wet AMD pivotal trials.
The clinical-stage biopharmaceutical company, focused on developing novel therapies for retinal diseases including wet age-related macular degeneration (wet AMD), will make its presentation available via webcast. The executive team will be available for one-on-one meetings from January 13-16, 2025. The presentation will be accessible through the company's website for 30 days following the event.
Details
News Market Reaction – OPT
The recorded move for OPT in the trading session of this news was +2.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Business update to include masked Phase 3 patient demographics and baseline characteristics
Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California
MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 15, 2025 at 5:15 PM PT.
Dr. Guerard will provide an update on the business, including masked patient demographics and baseline characteristics from the sozinibercept Phase 3 wet AMD pivotal trials. Opthea’s executive team will attend the conference and be available for one-on-one meetings January 13-16, 2025.
The live webcast and presentation will be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/, where the replay will be available for 30 days.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
| Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 | Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com |
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.